Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
29.61
-0.59 (-1.97%)
Streaming Delayed Price
Updated: 2:15 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
↗
August 23, 2024
Via
Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
↗
August 15, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
↗
July 30, 2024
Via
Benzinga
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
July 10, 2024
Via
Benzinga
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 14, 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Keep on Your Clinical Radar
↗
July 23, 2024
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.
Via
InvestorPlace
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 23, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
↗
July 10, 2024
FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant...
Via
Benzinga
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
July 08, 2024
Via
Benzinga
The 7 Best Under $10 Stocks to Buy in July 2024
↗
July 06, 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
Via
InvestorPlace
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
June 20, 2024
Via
Benzinga
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
↗
June 13, 2024
These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout.
Via
InvestorPlace
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 10, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
May 15, 2024
Via
Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
↗
May 15, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
↗
May 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 15, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
May 15, 2024
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!
Via
InvestorPlace
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 14, 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
↗
May 14, 2024
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
